CRDF Cardiff Oncology Inc

$CRDF friends, after being part of this little community for over six years, I feel I owe many of you a proper goodbye. Due to mounting costs related to my wife's battle with stage 4 colon cancer, I have liquidated my position here. I don't expect that I will be in a position to buy back in unfortunately. The combined rising costs of living and medical costs have wrecked my family's finances. And the cost of being away from work for so long is that my business is in shambles. As all of this is happening, my wife's doctors have moved her from 4b to 4c. I now am being forced to accept that the chance of us saving her life is far beyond a long stretch. She herself is now talking about the end as something that is not avoidable. I wish each of you the best. I wish the patients in the Onvansertib trials the best. I wish their loved ones the best. And of course, I wish the team at Cardiff Oncology the best. Goodbye friends.

$CRDF Not that it matters but HCW did just rerate CRDF with a $9 price target. I know it's a tall order given all retail investors have been through but exercise some additional patience. There was a lot of doom and gloom over this lawsuit with people suggesting NMS was going to bleed us dry or steal the asset. Now some of those same voices are predicting mass dilution. Take a deep breath. I don't know precisely how CRDF will go about funding CRDF-005 and what the near term impact will be to retail investors but this will sort it out some time in Q4. I still think a partnership with upfront cash of $200M+ in exchange for a slice of future sales is the most viable path but that remains to be seen. All I know for certain is the CRDF will be worth exponentially more than it is today at some point in the next 12-24 months. This has turned out to be a much longer term investment than I anticipated but that's biotech for you. GLTL

$CRDF I just had a short conversation with an oncologist....he mentioned the horrendous toxicities of Rasonque for pancreatic .....he can't believe it was approved they are so bad but they have nothing else....he told me they are now pushing it hard for mCRC and he is starting a 3rd line pt on it...I'm assuming that is off label....I brought up Onva which he was not aware of....he said any drug that extends mPFS by 6 months in first line mCRC would be huge.....also having to use Folfiri with it would present no problem at all and would be immediately adopted

$CRDF Next targets are gaps ,90 then 2,84 when the last collapse started end of january,the day of Erlander resignation. The legal thing has been closed as Logic suggested,no Surprise as I have Always said. Now Let's focus on ovansertib. The benefits of this product are Still not fully understood in This board, I am expecting more news soon. Strong buy.

$CRDF let’s do it for Bubba. Cardiff hits $10 before January I will donate $100K to him mark this post. Any one else.

$CRDF there is really nothing much to talk about until they reveal more data and/or partnerships. It’s the waiting game

$CRDF The stock should gap up significantly on this news. The market has been pricing in a ~50% probability of total loss, and the opposite happened. So the risk is now gone. The remaining risks (Phase 3 execution, financing, commercialization) are standard biotech risks — and with practice-changing Phase 2 data and an FDA-aligned registrational program, Cardiff is now one of the most attractive Phase 3 oncology assets available. Cardiff could now focus on BD/ partnership and funding for start of phase 3 in Q1 2027!

$CRDF The market's response has been the same at every stage: Stronger data → "Show me randomized data." Randomized data looks good → "Show me a registrational path." Registrational path appears possible → "Resolve the litigation." Litigation gets resolved → "Show me Phase 3." At some point, investors need to ask whether they're evaluating risk or simply pushing value recognition further into the future. Every major milestone reduces uncertainty. Yet the valuation often acts as if none of the prior milestones happened.

$CRDF Assuming that the mPFS has still not been reached by October 22nd that will be the 20 month mark. That is a remarkable PFS maturity. January-Feb of 2027 will represent 24 months. That kind of data is going to attract a partnership to fund the phase 3 or even possibly acquisition. Hang in there, patience is key at this stage. Good luck to all and have a wonderful weekend!

$CRDF I will predict a big price jump next week, much bigger than we saw this week with the positive news!!

$CRDF Have been holding a heavy bag here for years. Added a little big today to celebrate! 😂

$CRDF I just want an update on data. Let’s see what we got here. I’m not going anywhere. I’m going down with the ship or sailing to uncharted islands. Just hope it’s uncharted islands. That sounds kinda fun to me.

$CRDF Here is more relief from any other anxiety out there. Hopefully no one asks about the PI that was never granted. 81 Filed & Entered: 09/16/2026 Terminate Hearings Docket Text: MINUTE ORDER by Magistrate Judge Jill L. Burkhardt: As the parties have filed a Joint Stipulation of Dismissal [80], the Court hereby VACATES the 09/16/2026, Case Management and Status Conferences. (nxo.) (Entered on 09/16/2026

$CRDF pacira was just acquired in which Pace was a director there until 2024. Lets see if lightning strikes twice

$CRDF we will likely see an update before or during ESMO in late October. All the key GI thought leaders from europe will be in attendance and these meetings are the best for companies to meet with them. I hope to see EMA feedback is ready so the team can discuss the FDA/EMA blessed phase 3 study design. Also the team can finalize which sites to pick in europe. Also big pharma likes to announce acquisition or partnerships at the start of large conferences. With the settlement agreeement, Mani has to evaluate all her options. Her experience as a biotech equity investor she will know how to maximize the best deal for stakeholders.

$CRDF Here it is for this waiting for it 80 Filed & Entered: 09/16/2026 Motion to Dismiss Docket Text: Joint MOTION to Dismiss Joint Stipulation of Voluntary Dismissal by Cardiff Oncology, Inc.. (Merrill, Kourtney)

$CRDF Onvansertib has an addressable market of $10B in the US alone. That makes it one of the most valuable oncology drugs in development at the moment. There is zero chance that phase 3 doesn’t get funded. Get your head out of the sand and buy this at a price today that you’ll look back in disbelief.

$CRDF the short squeeze is now in effect. The settlement resolved all license uncertainty and both parties joined forces to advance this to Phase 3. Only uncertainty now is the funding of the trial, but thats going to solve on its own. Timing of onvansertib aligns will with massive upcoming LOEs and a phase 3 ready asset like this is a no brainer. Pressure now on big pharma on whom makes the best offer

$CRDF It's rather funny to see all these nervous people coming out before the weekend 😁. Recent legal news already forgotten. I Say strong buy

$CRDF Nice close to give us some optimism for next week. I know everyone is disappointed that we didn't rocket up immediately after the settlement, but sometimes the market reacts slowly or some kind of manipulation is giong on behind the scene. If the thesis is right, the market will eventually come around.